Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unified Code Name System for Drugs Set for Year-end Launch (China)

This article was originally published in PharmAsia News

Executive Summary

Wang Jinxia, vice chairman of the China Association of Pharmaceutical Commerce, says that China will launch a long-awaited unified code name system in the pharmaceutical industry as soon as the end of 2007. Wang is one of three people responsible for drafting the system. All drugs in China will be included in the new system and each medicine will be given a code name for wide recognition and digital management. "Everything is ready (for the system) and it only needs government bureaus' approval," Wang said during a Sinopharm Medicine Holdings Co. event to adopt a new IT system. Previously, drugs in China were written in Chinese, English, Latin or just numbers, lacking a unified code name system. Preparations for the system were first undertaken in 1997 but implementation has been delayed due to bureaucratic infighting over control of the system. (Click here for more

You may also be interested in...



China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel